Dianthus Therapeutics, Inc. Common Stock (DNTH) Financials
Key financial figures for Dianthus Therapeutics, Inc. Common Stock (Q3 2026).
Dianthus reports Q3 2026 net loss of $46.6 million ($0.81 per share) with about $1.2 billion of cash, which it says funds operations into 2030. Net loss was $46.6 million, or $0.81 per share (basic and diluted), versus $36.8 million, or $0.97 per share, in Q3 2025. Loss from operations was $58.5 million versus $40.3 million a year earlier. R&D expense rose to $45.6 million from $32.5 million, which the release attributes primarily to higher clinical costs and increased headcount supporting claseprubart Phase 2 and Phase 3 development plus DNTH212 and DNTH312 work. G&A was $14.1 million versus $8.2 million, primarily on headcount. On the outlook: The release carried no revenue or earnings guidance. Management said approximately $1.2 billion of cash as of September 30, 2026 provides expected runway into 2030, and guided clinical timelines: MoMeNtum (MMN) Phase 2 top-line in December 2026, CAPTIVATE (CIDP) Part A top-line by YE'27 and Part B by YE'28, EMERGE (gMG) top-line in 2H'28, DNTH212 Part A healthy volunteer preliminary data in Q1'27. Figures are for Q3 2026, as Dianthus Therapeutics reported them.
- Revenue
- $1M
- Net Income
- -$47M
- EPS
- $-0.81
- Total Assets
- $1.3B
- Operating Cash Flow
- -$50M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q3 FY2026 | $1M | -$47M | -$0.81 | -4832.4% | -$51M |
| Q2 FY2026 | $761K | -$50M | -$0.90 | -8079.11% | -$49M |
| Q1 FY2026 | $463K | -$41M | -$0.85 | -10050.32% | -$29M |
| Q4 FY2025 | $284K | $98M | $2.59 | -24486.27% | -$47M |
| Q3 FY2025 | $396K | -$37M | -$0.97 | -10173.74% | -$31M |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $2M | -$162M | -$4.20 | -8739.34% | -$129M |
| FY2024 | $6M | -$85M | -$2.55 | -1633.74% | -$78M |
| FY2023 | $3M | -$44M | -$8.45 | -1704.67% | -$37M |
Frequently asked questions
What was Dianthus Therapeutics's revenue last quarter?
Dianthus Therapeutics reported revenue of $1.2 million for Q3 FY2026, up 205.6% from the same period a year earlier.
Is Dianthus Therapeutics profitable?
Not in its most recent reported period. Dianthus Therapeutics reported a net loss of $46.6 million for Q3 FY2026, a net margin of -3854.79% on revenue.
How has Dianthus Therapeutics's margin trended?
Operating margin was -4832.4% in Q3 FY2026, compared with -10173.74% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.
How much free cash flow did Dianthus Therapeutics generate?
Dianthus Therapeutics generated free cash flow of -$50.7 million in Q3 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for Dianthus Therapeutics, Inc. Common Stock on SentiSense, with up to forty quarters and twenty fiscal years of history.